Oracle Health Sciences Reimagines Clinical Development Technology with New Cloud-Based eClinical Environment of the Future

Go back to Oracle Health Sciences Reimagines Clinical Development Technology with New Cloud-Based eClinical Environment of the Future

Jefferies Reiterates Buy on Oracle (ORCL) Ahead of 4Q Release

June 20, 2017 7:20 AM EDT

Jefferies reiterated a Buy rating and $52.00 price target on Oracle (NYSE: ORCL) ahead of the company's 4Q earnings report.

Analyst John DiFucci expects ORCL's 4Q to be driven by continued strength in Cloud signings and less moderation of the on premise... More